Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-549	Omipalisib	2	72	sigmoid	sigmoid	BT549 omipalisib 0 2 72	8	1.990	0.0104	-0.291	0.751	0.026	-0.32	0.542	0.966	4.09e-05	NA	0.0175	0.127	0.422	0.011	0.118	0.58	0.953	0.000102	NA
BT-549	TGX221	2	72	sigmoid	sigmoid	BT549 TGX-221 0 2 72	8	1.927	17.5	0.772	0.0551	123.0	-1.0	0.562	0.907	0.000795	NA	32.3	0.792	0.949	32.3	3.45e-05	0.58	0.899	0.00102	NA
HCC70	Trametinib	2	72	sigmoid	sigmoid	HCC70 trametinib 0 2 72	8	1.721	0.506	0.504	0.395	0.00469	0.467	0.581	0.944	0.000179	NA	Inf	0.612	0.687	0.00389	0.585	0.57	0.948	0.000138	NA
HCC1806	PIK-93	3	72	sigmoid	sigmoid	HCC1806 PIK-93 0 3 72	8	3.206	56.0	0.873	0.0337	320.0	-0.872	0.579	0.859	0.00279	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC1806	PIK-93	2	72	sigmoid	sigmoid	HCC1806 PIK-93 0 2 72	8	2.838	41.1	0.857	0.038	265.0	-1.0	0.59	0.858	0.00286	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC1806	PIK-93	1	72	sigmoid	sigmoid	HCC1806 PIK-93 0 1 72	8	2.753	44.0	0.853	0.0391	304.0	-1.0	0.568	0.858	0.00285	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
Hs 578T	CAL-101	1		sigmoid	sigmoid	Hs578T idelalisib 1	8	2.050	27.9	0.72	0.0764	4.56	0.356	0.688	0.945	0.000168	NA	18.7	0.734	0.925	18.7	0.0	0.568	0.941	0.000203	NA
HCC1806	MK2206	2	72	sigmoid	sigmoid	HCC1806 MK-2206 0 2 72	8	2.831	51.9	0.823	0.0489	320.0	-0.668	0.467	0.981	7.01e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.45e-05	NA
HCC1806	MK2206	3	72	sigmoid	sigmoid	HCC1806 MK-2206 0 3 72	8	3.199	74.1	0.843	0.0434	320.0	-0.491	0.468	0.981	6.96e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.46e-05	NA
HCC1806	MK2206	1	72	sigmoid	sigmoid	HCC1806 MK-2206 0 1 72	8	2.746	47.7	0.818	0.0504	320.0	-0.715	0.466	0.981	7.02e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.46e-05	NA
Hs 578T	ZSTK474	2		sigmoid	sigmoid	Hs578T ZSTK474 2	8	2.554	0.715	0.187	0.263	5.92	-0.896	0.485	0.995	1.27e-07	NA	0.583	0.264	0.722	0.583	0.0	0.56	0.993	3.28e-07	NA
HCC70	Dactolisib	2	72	sigmoid	sigmoid	HCC70 dactolisib 0 2 72	8	1.677	0.312	0.238	0.341	0.195	0.103	0.493	0.954	9.66e-05	NA	2.24	0.447	0.738	0.0858	0.419	0.56	0.954	9.8e-05	NA
HCC38	Omipalisib	2	72	sigmoid	sigmoid	HCC38 omipalisib 0 2 72	8	2.124	0.0404	-0.47	0.634	0.45	-1.0	0.456	0.979	9.71e-06	NA	0.0507	0.0595	0.494	0.0507	0.0	0.556	0.96	6.44e-05	NA
HCC38	ZSTK474	2	72	sigmoid	sigmoid	HCC38 ZSTK474 0 2 72	8	2.253	1.63	0.396	0.196	2.18	-0.0865	0.554	0.984	4.3e-06	NA	2.0	0.445	0.803	1.14	0.135	0.556	0.982	5.91e-06	NA
BT-549	CAL-101	2	72	sigmoid	sigmoid	BT549 idelalisib 0 2 72	8	1.975	Inf	0.792	0.0561	4.65	0.526	0.693	0.933	0.000307	NA	43.0	0.805	0.946	43.0	0.0	0.548	0.932	0.000314	NA
BT-20	Trametinib	1	72	sigmoid	sigmoid	BT20 trametinib 0 1 72	8	2.016	14.3	0.54	0.225	0.135	0.458	0.534	0.989	1.3e-06	NA	Inf	0.59	0.791	0.0955	0.534	0.545	0.989	1.43e-06	NA
BT-549	Alpelisib	2	72	sigmoid	sigmoid	BT549 alpelisib 0 2 72	8	1.927	Inf	0.832	0.0409	4.24	0.663	0.548	0.706	0.0254	NA	Inf	0.844	0.962	4.26	0.686	0.542	0.696	0.0282	NA
BT-20	WYE-125132	2	72	sigmoid	sigmoid	BT20 WYE-132 0 2 72	8	2.053	0.012	0.142	0.633	0.00936	0.072	0.621	0.909	0.000752	NA	0.0232	0.316	0.475	0.00613	0.255	0.536	0.894	0.00119	NA
Hs 578T	AS605240	2		sigmoid	sigmoid	Hs578T AS-605240 2	8	2.547	1.89	0.43	0.194	1.81	0.011	0.541	0.988	1.81e-06	NA	1.6	0.426	0.784	0.971	0.117	0.532	0.983	4.67e-06	NA
Hs 578T	AZD-6482	1		sigmoid	sigmoid	Hs578T AZD6482 1	8	2.041	2.04	0.401	0.177	18.5	-1.0	0.498	0.986	2.92e-06	NA	3.16	0.484	0.835	3.16	0.0	0.532	0.98	7.93e-06	NA
HCC38	AS605240	2	72	sigmoid	sigmoid	HCC38 AS-605240 0 2 72	8	2.200	17.4	0.642	0.114	4.07	0.256	0.493	0.936	0.000265	NA	46.2	0.648	0.882	1.68	0.411	0.522	0.929	0.000356	NA
HCC70	AZD-6482	1	72	sigmoid	sigmoid	HCC70 AZD6482 0 1 72	8	1.368	0.0982	0.0128	0.462	0.205	-0.212	0.481	0.975	1.49e-05	NA	0.767	0.394	0.704	0.121	0.305	0.509	0.973	1.9e-05	NA
BT-20	Alpelisib	2	72	sigmoid	sigmoid	BT20 alpelisib 0 2 72	8	1.692	0.253	-0.0994	0.405	2.25	-1.0	0.503	0.835	0.00451	NA	0.612	0.259	0.698	0.612	0.0	0.507	0.764	0.0131	NA
HCC38	Trametinib	1	72	sigmoid	sigmoid	HCC38 trametinib 0 1 72	8	1.733	0.162	0.196	0.407	0.173	-0.0184	0.559	0.948	0.000139	NA	0.568	0.41	0.686	0.161	0.234	0.501	0.947	0.000151	NA
HCC70	AZD-6482	3	72	sigmoid	sigmoid	HCC70 AZD6482 0 3 72	8	2.532	1.43	0.435	0.247	0.421	0.226	0.492	0.983	4.63e-06	NA	1.13	0.431	0.729	0.208	0.286	0.5	0.982	6.2e-06	NA

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)